Adam Raben, MD
Radiation Oncology · Newark, DENPI 1306888961
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,160 of the $84,061 with a category attached, or 69.2%. E.r. Squibb & Sons, L.L.C. accounts for 86.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $31,538 and has fallen 99.8% since, to $48 in 2025.
Across 90 payments — averaging $934.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$73K
- Viewray Technologies Inc$4K
- AstraZeneca$4K
- Isoray, Inc$2K
- Myriad Genetic Laboratories, Inc.$279
- Angiodynamics, Inc.$59
- plus $230 from 6 others
What the payments were for
- Consulting fees$14,68417%
- Speaking & faculty fees$58,16069%
- Travel & lodging$8,60910%
- Food & beverage$2,6083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 54 | $72,528 |
| Viewray Technologies Inc | 8 | $4,260 |
| AstraZeneca | 8 | $4,245 |
| Isoray, Inc | 9 | $2,460 |
| Myriad Genetic Laboratories, Inc. | 3 | $279 |
| Angiodynamics, Inc. | 1 | $59 |
| Boston Scientific | 1 | $57 |
| Teleflex LLC | 2 | $55 |
| Foundation Medicine, Inc. | 1 | $50 |
| Clovis Oncology, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$67,932
- IMFINZI$4,107
- MRIdian LINAC$3,985
- Brachytherapy Source$2,393
- Prolaris$274
- MRIdian$164
How this compares
Too few radiation oncology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pentoxifylline | 99 | $2,431 |
| Bicalutamide | 24 | $713 |
| Tamsulosin Hcl | 53 | $616 |
| Mometasone Furoate | 28 | $367 |
| Gabapentin | 25 | $287 |
| Fluconazole | 14 | $183 |
| Methylprednisolone | 15 | $77 |
| Dexamethasone | 15 | $64 |
| Lorazepam | 15 | $22 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Newark
- Jon StrasserNewark$365K
- Sunjay ShahNewark$7K
- Gaurav ShuklaNewark$3K
- Lindsay RomakNewark$3K
- Lana de Souza LawrenceNewark$333
- Christopher KoprowskiNewark$20
- Andrejs StraussRehoboth Beach$2K
- Owen ThomasRehoboth Beach$1K
- Jennifer HungRehoboth Beach$715
- Tony LeeDover$567
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.